These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 33913372)

  • 1. PANX2 and brain lower grade glioma genesis: A bioinformatic analysis.
    Xu X; Hao Y; Xiong S; He Z
    Sci Prog; 2021; 104(2):368504211011836. PubMed ID: 33913372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
    Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
    Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
    Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
    BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
    Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
    Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serine Incorporator 2 (SERINC2) Expression Predicts an Unfavorable Prognosis of Low-Grade Glioma (LGG): Evidence from Bioinformatics Analysis.
    Qi C; Lei L; Hu J; Wang G; Liu J; Ou S
    J Mol Neurosci; 2020 Oct; 70(10):1521-1532. PubMed ID: 32642801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of genes related to low-grade glioma progression and prognosis based on integrated transcriptome analysis.
    Jiang Y; He J; Guo Y; Tao H; Pu F; Li Y
    J Cell Biochem; 2020 Jun; 121(5-6):3099-3111. PubMed ID: 31886582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EFNA1 is a potential key gene that correlates with immune infiltration in low-grade glioma.
    Hao YP; Wang WY; Qiao Q; Li G
    Medicine (Baltimore); 2021 Jun; 100(22):e26188. PubMed ID: 34087884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Hub Gene GRIN1 Correlated with Histological Grade and Prognosis of Glioma by Weighted Gene Coexpression Network Analysis.
    Yang A; Wang X; Hu Y; Shang C; Hong Y
    Biomed Res Int; 2021; 2021():4542995. PubMed ID: 34840971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcriptional expression of ZICs as an independent indicator of survival in gliomas.
    Han Z; Jia J; Lv Y; Wang R; Cao K
    Sci Rep; 2021 Sep; 11(1):17532. PubMed ID: 34475426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Single-cell transcriptome analysis of multigrade glioma heterogeneity and immune microenvironment revealed potential prognostic biomarkers].
    Liu J; Xu K; Ma L; Wang Y
    Sheng Wu Gong Cheng Xue Bao; 2022 Oct; 38(10):3790-3808. PubMed ID: 36305410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Core Biomarkers Associated with Outcome in Glioma: Evidence from Bioinformatics Analysis.
    Geng RX; Li N; Xu Y; Liu JH; Yuan FE; Sun Q; Liu BH; Chen QX
    Dis Markers; 2018; 2018():3215958. PubMed ID: 30405856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study on the Prognostic Values of Dynactin Genes in Low-Grade Glioma.
    Su X; Li H; Chen S; Qin C
    Technol Cancer Res Treat; 2021; 20():15330338211010143. PubMed ID: 33896271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of Genome-Scale Integrated Analysis to Identify Key Genes and Potential Molecular Mechanisms in Recurrence of Lower-Grade Brain Glioma.
    Deng T; Gong YZ; Wang XK; Liao XW; Huang KT; Zhu GZ; Chen HN; Guo FZ; Mo LG; Li LQ
    Med Sci Monit; 2019 May; 25():3716-3727. PubMed ID: 31104065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prokineticins as a Prognostic Biomarker for Low-Grade Gliomas: A Study Based on The Cancer Genome Atlas Data.
    Zhong J; Xiang D; Ma X
    Biomed Res Int; 2022; 2022():2309339. PubMed ID: 35845958
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Ma W; Zhang K; Bao Z; Jiang T; Zhang Y
    Front Immunol; 2021; 12():659659. PubMed ID: 33936093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PLEKHA4 Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Glioma.
    Zhang W; Li L; Bian PP; Luo QP; Xiong ZT
    Biomed Res Int; 2023; 2023():4504474. PubMed ID: 36714030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pannexin2 as a novel growth regulator in C6 glioma cells.
    Lai CP; Bechberger JF; Naus CC
    Oncogene; 2009 Dec; 28(49):4402-8. PubMed ID: 19749789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-193a-3p Promotes the Invasion, Migration, and Mesenchymal Transition in Glioma through Regulating BTRC.
    Zhou DD; Li HL; Liu W; Zhang LP; Zheng Q; Bai J; Hu YQ; Yin CG; Lv SJ; Zhang BG
    Biomed Res Int; 2021; 2021():8928509. PubMed ID: 33628829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Potential of Secreted Modular Calcium-Binding Protein 1 in Low-Grade Glioma.
    Wang J; Xia S; Zhao J; Gong C; Xi Q; Sun W
    Front Mol Biosci; 2021; 8():666623. PubMed ID: 34869577
    [No Abstract]   [Full Text] [Related]  

  • 20. The promising novel biomarkers and candidate small molecule drugs in lower-grade glioma: Evidence from bioinformatics analysis of high-throughput data.
    Zhang B; Wu Q; Xu R; Hu X; Sun Y; Wang Q; Ju F; Ren S; Zhang C; Qi F; Ma Q; Wang Z; Zhou YL
    J Cell Biochem; 2019 Sep; 120(9):15106-15118. PubMed ID: 31020692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.